Policymakers should proceed with caution in allowing Medicare Advantage plans to use step therapy for physician-administered Part B drugs: First, due to variability in patient response to drugs in the same therapeutic class; second, the lack of evidence to suggest step therapy saves patients money.
Medicare Advantage Plan Proposed Use Of Step Therapy For Part B Drugs
